Durso Timothy August sold $4.7M of MANE

Durso Timothy August (Chief Technical Officer) sold 43,500 shares of Veradermics, Inc (MANE) at an average of $107.82 ($106.71–$111.28, $4.69M total) across 5 trades on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Durso Timothy August
Published Aug 19, 2026, 1:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 1:14 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Neutral
medium confidence
Mentioned
$MANE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANENeutralLow
01

Why it matters

This is a primary disclosure of insider selling by the CTO, executed across five trades at $106.71 to $111.28 per share, totaling about $4.69M, with a stated 10b5-1 plan.

02

Market read

Traders may monitor for sentiment effects from insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The filing does not state whether the insider retained meaningful exposure beyond the post-sale holdings, nor does it provide context on total compensation or prior sale cadence.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-18 for sales executed 2026-08-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Veradermics, Inc (MANE).

Company-level read

Ticker impact

$MANENeutralMedium confidence
Context

Form 4 shows MANE CTO Durso Timothy August sold 43,500 shares in open-market trades for about $4.69M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction with a stated 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through because the disclosure is company-specific and lacks operational or regulatory details.

None indicated.

None indicated.

Counterpoint

The sale may reflect routine liquidity needs under a scheduled 10b5-1 plan, so it may not signal deteriorating fundamentals.

Key entities

  • Veradermics, Inc

    Company whose insider transaction is disclosed on SEC Form 4.

  • Durso Timothy August

    Chief Technical Officer who sold 43,500 shares in open-market trades.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, which typically reduces interpretive weight of the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.